Friedman Ohana Rachel, Levin Sergiy, Wood Monika G, Zimmerman Kris, Dart Melanie L, Schwinn Marie K, Kirkland Thomas A, Hurst Robin, Uyeda H Tetsuo, Encell Lance P, Wood Keith V
Promega Corporation , Madison, Wisconsin 53711, United States.
Promega Biosciences LLC , San Luis Obispo, California 93401, United States.
ACS Chem Biol. 2016 Sep 16;11(9):2608-17. doi: 10.1021/acschembio.6b00408. Epub 2016 Aug 3.
The benefits provided by phenotypic screening of compound libraries are often countered by difficulties in identifying the underlying cellular targets. We recently described a new approach utilizing a chloroalkane capture tag, which can be chemically attached to bioactive compounds to facilitate the isolation of their respective targets for subsequent identification by mass spectrometry. The tag minimally affects compound potency and membrane permeability, enabling target engagement inside cells. Effective enrichment of these targets is achieved through selectivity in both their rapid capture onto immobilized HaloTag and their subsequent release by competitive elution. Here, we describe a significant improvement to this method where selective elution was achieved through palladium-catalyzed cleavage of an allyl-carbamate linkage incorporated into the chloroalkane capture tag. Selective tag cleavage provided robust release of captured targets exhibiting different modes of binding to the bioactive compound, including prolonged residence time and covalent interactions. Using the kinase inhibitors ibrutinib and BIRB796 as model compounds, we demonstrated the capability of this new method to identify both expected targets and "off-targets" exhibiting a range of binding affinities, cellular abundances, and binding characteristics.
化合物库的表型筛选所带来的益处常常被识别潜在细胞靶点的困难所抵消。我们最近描述了一种利用氯代烷烃捕获标签的新方法,该标签可以化学连接到生物活性化合物上,以促进其各自靶点的分离,随后通过质谱进行鉴定。该标签对化合物的效力和膜通透性影响最小,能够在细胞内实现靶点结合。通过对这些靶点快速捕获到固定化的卤代酶标签上以及随后通过竞争性洗脱实现释放的选择性,实现了这些靶点的有效富集。在这里,我们描述了对该方法的一项重大改进,即通过钯催化裂解并入氯代烷烃捕获标签中的烯丙基 - 氨基甲酸酯键来实现选择性洗脱。选择性标签裂解能够有力地释放被捕获的靶点,这些靶点与生物活性化合物表现出不同的结合模式,包括延长的停留时间和共价相互作用。使用激酶抑制剂依鲁替尼和BIRB796作为模型化合物,我们证明了这种新方法能够识别具有一系列结合亲和力、细胞丰度和结合特征的预期靶点和“脱靶”靶点。